A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder

International Journal of Psychiatry in Clinical Practice

Volumn 15, Issue 4, 2011, Pages 263-269

  Matsunaga, Hisato ^a   Hayashida, Kazuhisa ^a   Maebayashi, Kensei ^a   Mito, Hironori ^a   Kiriike, Nobuo ^b  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aripiprazole; Atypical antipsychotic drug; Augmentation; Obsessive compulsive disorder; Treatment refractory

Indexed keywords

ARIPIPRAZOLE; FLUVOXAMINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGITATION; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE THERAPY; COMPULSION; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; IMPULSIVENESS; INSOMNIA; LONGITUDINAL STUDY; MALE; MONOTHERAPY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; QUINOLONES; SEROTONIN UPTAKE INHIBITORS;

EID: 80053989053     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2011.605958     Document Type: Article

References (25)

1. Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin N Am 2006;29:553-84.
2. Stein DJ, Ipser JC, Baldwin DS, Bandelow B. Treatment of obsessive-compulsive disorder. CNS Spectr 2007;12(Suppl 3):28-35.
3. Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ, et al. Pharmacotherapy augmentation strategies in treatmentresistant anxiety disorders. Cochrane Database Syst Rev (Online) 2006;18:CD005473.
4. Pallanti S, Quercioli L. Treatment-refractory obsessivecompulsive disorder; Methodological issues, operational defi nitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:400-12.
5. Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatmentresistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007;17:79-93. (Pubitemid 44779187)
6. Matsunaga H, Nagata T, Hayashida, Ohya K, Kiriike N, Stein. DJ. A long-term effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009; 70(6):863-8.
7. Connor KM, Payne VM, Gadde KM, Zhang W. The use of aripiprazole in obsessive-compulsive disorder; preliminary observations in 8 patients. J Clin Psychiatry 2005;66:49-51.
8. Lai C-H. Aripiprazole treatment in an adolescent patient with chronic motor tic disorder and treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol 2009;12:1291-3.
9. Ginsberg DL. Aripiprazole augmentation of clomipraminerefactory obsessive-compulsive disorder. Primary Psychiatry 2007;14:19-21.
10. Friedman S, Abdallah TA, Oumaya M. Rouillon F, Guelfi JD. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder. J Clin Psychiatry 2007;68: 972-3. (Pubitemid 47015504)
11. Pessina E, Albert U, Bogetto F, Maina G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatmentresistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol 2009; 24:265-9.
12. Sarkar R, Klein J, Kruger S. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psychopharmacology 2008;197:687-8.
13. Stroch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety 2008;25:172-4. (Pubitemid 351341964)
14. Yang K-C, Su T-P, Chou Y-H. Effectiveness of aripiprazole in treating obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:585-6. (Pubitemid 351178972)
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
16. First MB, Spitzer RL, Gibbon M, Williams JB. The Structured Clinical Interview for DSM-IV Axis I Disorders. New York: Biometric Research, New York State Psychiatric Institute; 1997.
17. Goodman WK, Price L, Rasmussen SA, Mazure C, Fleishmann RL, Hill C, et al. The Yale-Brown Obsessive-Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-11. (Pubitemid 19278229)
18. Goodman WK, Price L, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The Yale-Brown Obsessive-Compulsive Scale, II: validity. Arch Gen Psychiatry 1989;46:1012-16.
19. Nakajima T, Nakamura M, Taga C, Yamagami S, Kiriike N, Nagata T, et al. Reliability and validity of the Japanese version of the Yale-Brown Obsessive-Compulsive Scale. Psychiatry Clin Neurosci 1995;49:121-6.
20. Bloch MH, Landeros-Weisenberger A, Rasario MC, Pittenger C, Leckman JF. Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry 2008;165:1532-42.
21. Denys D, Fineberg N, Carey PD, Stein DJ. Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry 2007;61:412-14. (Pubitemid 46108696)
22. Masi G, Pfanner C, Millepiedi S, Stefano B. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2010;30:688-93.
23. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and neurobiology of schizophrenia. CNS Drugs 2006;20:389-409. (Pubitemid 43763739)
24. Fukui H, Murai T. Severe weight gain induced by combination treatment with risperidone and paroxetine. Clin Neuropharmacol 2002;25:269-71. (Pubitemid 35239486)
25. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine pharmacokinetic and pharmacodynamic profi le. Clin Pharmacokinet 1999;37:177-93.